Global Phase III KEYNOTE-C93 data presented and published online 26 October show markedly longer progression-free survival with pembrolizumab alone than carboplatin–paclitaxel in untreated or recurrent mismatch-repair-deficient advanced endometrial cancer. Overall survival has not yet…
Iovance’s final 24-patient Phase 2 cohort of lifileucel plus pembrolizumab in untreated advanced melanoma shows 62.5% confirmed response, 29.2% complete response, and median overall survival not reached after 50.9 months median study follow-up. Durability…
The European Commission authorized pembrolizumab plus enfortumab vedotin before cystectomy and continued afterward for adults with resectable muscle-invasive bladder cancer. The decision extends a clinically validated PD-1 plus ADC regimen into an EU perioperative…
A specialized Dutch court found that Merck’s subcutaneous pembrolizumab product infringes Halozyme’s MDASE patent EP 2,797,622 and ordered MSD BV to stop specified manufacturing, distribution, marketing, use, import, and stocking activities tied to Keytruda…
Inhibrx reported primary-endpoint results from the randomized Phase II portion of HexAgon in first-line, treatment-naive, PD-L1 CPS at least 20 metastatic or unresectable recurrent head and neck squamous-cell carcinoma. INBRX-106 plus pembrolizumab produced a…
Akeso reported that first-line ivonescimab monotherapy produced a statistically significant overall-survival benefit versus pembrolizumab in HARMONi-2, a randomized, double-blind Phase III study in 398 patients with PD-L1-positive advanced non-small-cell lung cancer in China. The…
